Vigamox®
Moxifloxacin 0.5% · ophthalmic solution
Antibiotic
Approved uses
Bacterial conjunctivitis
1 drop in the affected eye TID for 7 days.
OFF-LABELNot in the FDA label for this product
Bacterial keratitis
Trial regimen: 0.5% solution instilled hourly for 48 hours, then tapered by clinical response, in ulcers 2 to 8 mm.
RCT · n=61 · underpowered
Randomized three-arm trial, 61 patients (20 on moxifloxacin 0.5%, 21 on gatifloxacin 0.3%, 20 on fortified cefazolin 5% plus tobramycin 1.3%): 93% healed overall, no significant difference in mean time to heal (P = 0.98), and treatment failure (perforation or nonhealing ulcer) in 1 of 20 versus 2 of 20 on fortified antibiotics, with 62% culture positivity. The authors state the study failed to find a difference, which at 20 patients per arm is not a demonstration of equivalence. The report does not name the commercial product used.
Endophthalmitis prophylaxis at cataract surgery, intracameral
0.03 mL (150 mcg) of undiluted 0.5% solution injected into the anterior chamber at the end of phacoemulsification.
RCT · n=3,640 eyes
Prospective randomized partially masked single-site trial, 3,640 eyes: acute endophthalmitis within 6 weeks in 1 of 1,818 injected eyes (0.05%) versus 7 of 1,822 uninjected (0.38%), P = 0.035, with no difference in corrected distance acuity, endothelial cell density, IOP or central corneal thickness; both arms also received postoperative topical 0.5% moxifloxacin and 0.1% dexamethasone, so what was tested is the added injection. A retrospective before-and-after clinical registry of 617,453 cataract surgeries at 10 Aravind hospitals found 0.02% (64 of 314,638) with prophylaxis versus 0.07% (214 of 302,815) without (P < 0.001); that is a registry comparison, not a randomized one. A companion randomized substudy of 93 patients from the same group names the injected product as Vigamox solution and found no change in macular or choroidal thickness at day 30 or 60.
Contraindications
History of hypersensitivity to moxifloxacin, to other quinolones, or to any component of this product.
3 mL in a 4 mL bottle, 0.5% solution, 5 mg moxifloxacin base per mL
8-methoxy fluoroquinolone with a diazabicyclononyl ring at the C7 position. Its antibacterial action results from inhibition of topoisomerase II (DNA gyrase), an essential enzyme involved in the replication, transcription and repair of bacterial DNA, and of topoisomerase IV, which plays a key role in partitioning chromosomal DNA during bacterial cell division. Its mechanism differs from that of macrolides, aminoglycosides and tetracyclines, and there is no cross-resistance between moxifloxacin and those classes. Cross-resistance has been observed between systemic moxifloxacin and some other quinolones.
Warnings & Precautions
- Hypersensitivity reactions: Serious and occasionally fatal anaphylactic reactions have been reported with systemically administered quinolones, including moxifloxacin, some after the first dose and some with cardiovascular collapse, loss of consciousness, angioedema, airway obstruction, dyspnea, urticaria and itching. If an allergic reaction occurs, discontinue use. Serious acute reactions may require immediate emergency treatment, with oxygen and airway management as clinically indicated.
- Resistant organism overgrowth: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, examine the patient with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.
- Lens wear: Contact lenses are not appropriate while signs or symptoms of bacterial conjunctivitis are present.
Common Side Effects
The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing, in approximately 1% to 6% of patients. Nonocular adverse events reported at a rate of 1% to 4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.
Pregnancy: No adequate and well-controlled studies in pregnant women to inform drug-associated risk. Oral dosing in rats and monkeys and IV dosing in rabbits through organogenesis produced no adverse maternal or fetal effects at clinically relevant doses; reduced fetal weight and delayed skeletal development in rats, and abortion, malformations and delayed ossification in rabbits, appeared only at systemic exposures hundreds to thousands of times the human AUC at the ophthalmic dose, several of them maternally toxic. A pre- and postnatal rat study showed reduced pup birth weight and decreased prenatal and neonatal survival only at 500 mg/kg/day, about 277 times the human AUC and a maternally lethal dose.
Lactation: No data on presence in human milk, effects on the breastfed infant, or effects on milk production. Transfer into milk occurs in lactating rats after oral dosing, and systemic levels after topical ocular use are low.
Safety and effectiveness established in all ages, including neonates.